Embolic protection tech firm nets $6.7m in series B
This article was originally published in Clinica
Embrella Cardiovascular has secured $6.7m in a series B financing round led by BioStar Ventures and the MedFocus Fund. The new capital, which also included investments made by Edwards Lifesciences and Hatteras Venture Partners, will enable Wayne, Pennsylvania-based Embrella to complete European clinical trials of its Embolic Deflector device and submit the data for CE mark approval. The product will be used in procedures such as transcatheter aortic valve implantation, which is carried out on high-risk patients with severe aortic stenosis. The Embrella Embolic Deflector is designed to prevent emboli that are dislodged during the procedure from entering the brain by deflecting them away from the carotid arteries.